Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 4356-4363

  Hussain, Mahrukh M ^a   Kotz, Herbert ^a   Minasian, Lori ^a   Premkumar, Ahalya ^a   Sarosy, Gisele ^a   Reed, Eddie ^a   Zhai, Suoping ^a   Steinberg, Seth M ^a   Raggio, Miranda ^a   Oliver, Vyta Kulpa ^a   Figg, William D ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; GELATINASE A; INTERLEUKIN 8; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYAMIDO TRIAZOLE; CARBOXYAMIDO-TRIAZOLE; TRIAZOLE DERIVATIVE;

ARTICLE; CANCER PATIENT; CANCER RELAPSE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EPITHELIUM CELL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ADULT; AGED; COMPARATIVE STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; METABOLISM; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PAPILLARY CARCINOMA; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CARCINOMA, ENDOMETRIOID; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 0642307226     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.136     Document Type: Article

References (45)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805, 1991
3. Latorre A, De Lena M, Catino A: Epithelial ovarian cancer: Second and third line chemotherapy. Int J Oncol 21:179-186, 2002
4. Ozols RF, Rubin SC, Thomas GM, et al: Epithelial ovarian cancer, in Principles and Practice of Gynecologic Oncology (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 981-1058
5. Knopf K, Brown M, Kohn EC: Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer, 1980-1997. Proc Am Soc Clin Oncol 17:359a, 1998 (abstr)
6. Zidan J, Zohar S, Mijiritzky I, et al: Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. Isr Med Assoc J 4:597-599, 2002
7. Harper P: Current clinical practices for ovarian cancers. Semin Oncol 29:3-6, 2002
8. Gadducci A, Conte P, Cianci C, et al: Treatment options in patients with recurrent ovarian cancer. Anticancer Res 21:3557-3564, 2001
9. Kohn EC, Reed E, Sarosy G, et al: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56:569-573, 1996
10. Kohn EC, Figg WD, Sarosy GA, et al: Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 15:1985-1993, 1997
11. Berlin J, Tutsch KD, Arzoomanian RZ, et al: Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: Toxicity, bioavailability and the effect of food. Clin Cancer Res 8:86-94, 2002
12. Berlin J, Tutsch KD, Hutson P, et al: Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 15:781-789, 1997
13. Kohn EC, Liotta LA: L651582: A novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 82:54-60, 1990
14. Kohn EC, Sandeen MA, Liotta LA: In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 52:3208-3212, 1992
15. Kohn EC, Felder CC, Jacobs W, et al: Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 54:935-942, 1994
16. Kohn EC, Jacobs W, Kim YS, et al: Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505-21511, 1994
17. Kohn EC, Alessandro R, Spoonster J, et al: Angiogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 92:1307-1311, 1995
18. +2 influx. Biochem Biophys Res Commun 248:635-640, 1998
19. Masiero L, Lapidos KA, Ambudkar I, et al: Regulation of the RhoA pathway in human endothelial cell spreading on type IV collagen: Role of calcium influx. J Cell Sci 112:3205-3213, 1999
20. Luzzi KJ, Varghese HJ, MacDonald IC, et al: Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI): Computer assisted analysis. Angiogenesis 2:373-379, 1999
21. Wu Y, Palad AJ, Wasilenko WJ, et al: Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor, carboxyamido-triazole. Clin Cancer Res 3:1915-1921, 1997
22. Wasilenko WJ, Palad AJ, Somers KD, et al: Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer 68:259-264, 1996
23. Felder CC, Ma AL, Liotta LA, et al: The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther 257:967-971, 1991
24. Faehling M, Kroll J, Fohr KJ, et al: Essential role of calcium in vascular endothelial growth factor A-induced signaling: Mechanism of the anti-angiogenic effect of carboxyamidotriazole. FASEB J 16:1805-1807, 2002
25. Alessandro R, Masiero L, Liotta LA, et al: The role of calcium in the regulation of invasion and angiogenesis. In Vivo 10:153-160, 1996
26. Bauer KS, Cude KJ, Dixon SC, et al: Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric oxide synthase-vascular growth factor pathway. J Pharmacol Exp Ther 292:31-37, 2000
27. Garnier-Raveaud S, Usson Y, Cand F, et al: Identification of membrane calcium channels essential for cytoplasmic and nuclear calcium elevations induced by vascular endothelial growth factor in human endothelial cells. Growth Factors 19:35-48, 2001
28. Levy AP, Levy NS, Loscalzo J, et al: Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res 76:758-766, 1995
29. Wellner M, Maasch C, Kupprion C, et al: The proliferate effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta. Arterioscler Thromb Vasc Biol 19:178-185, 1999
30. Wilson L, Butcher CJ, Kellie S: Calcium ionophore A23187 induces interleukin-8 gene expression and protein secretion in human monocytic cells. FEBS Lett 325:295-298, 1993
31. Neufeld G, Cohen T, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22, 1999
32. Heinrich J, O'Rourke EC, Chen L, et al: Biological activity of the growth factor-induced cytokine N51: Structure-function analysis using N51/interleukin-8 chimeric molecules. Mol Cell Biol 14:2849-2861, 1994
33. 2+-mediated activation of the NF-kappaB pathway. J Clin Invest 105:79-92, 2000
34. Kulpa OV, Patton AM, Desai S, et al: Regulation of the proangiogenic microenvironment by carboxyamido-triazole. J Cell Physiol 197:139-148, 2003
35. Liotta LA, Kohn EC: The microenvironment of the tumor-host invasion field. Nature 411:375-379, 2001
36. Sieczkiewicz GJ, Hussain M, Kohn EC: Angiogenesis and metastasis. Cancer Treat Res 107:353-381, 2002
37. Bauer KS, Kohn EC, Lush RM, et al: Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: Use of a single model for simultaneous determination of changing parameters. J Pharmacokinet Biopharm 26:673-687, 1998
38. Simmons BR, Bauer KS, McCall NA, et al: An optimized method for the quantitation of carboxyamido-triazole (CAI) in human plasma with solid phase extraction and reversed phase HPLC. Anal Lett 30:2009-2021, 1997
39. D'Argenia DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134, 1979
40. Figg WD, Cole KA, Reed E, et al: Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction. Clin Cancer Res 1:797-803, 1995
41. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
42. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
43. Berridge MJ, Bootman MD, Lipp P: Calcium: A life and death signal. Nature 395:645-648, 1998
44. Jones MB, Krutzsch H, Shu H, et al: Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2:76-84, 2002
45. Liotta LA, Petricoin EF III, Ardekani AM, et al: General keynote: Proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 88:S25-S28; discussion S37-S42, 2003